Home Ovarian and Gynecologic Cancer Biomarkers Gynecologic Cancer Gene Panel: BRCA, Lynch Syndrome, RAD51, BRIP1, and Hereditary Risk

Gynecologic Cancer Gene Panel: BRCA, Lynch Syndrome, RAD51, BRIP1, and Hereditary Risk

By
Vita Library
-
31
Understand gynecologic cancer gene panels for BRCA1/2, Lynch syndrome, RAD51C, RAD51D, and BRIP1, including hereditary risk, result meaning, and next steps.

A gynecologic cancer gene panel looks for inherited pathogenic variants that can increase the risk of ovarian, fallopian tube, primary peritoneal, endometrial, and other cancers. The exact genes vary by laboratory and clinical history, but important groups include BRCA1 and BRCA2, ovarian-cancer susceptibility genes such as RAD51C, RAD51D, and BRIP1, and the Lynch syndrome genes MLH1, MSH2, MSH6, PMS2, and EPCAM. Some panels also include PALB2, STK11, PTEN, TP53, and other cancer-predisposition genes when relevant. Testing may explain why a cancer developed, guide risk-reducing care for the patient and relatives, and occasionally influence treatment. A germline panel is different from tumor sequencing: blood or saliva tests inherited DNA, while tumor testing can detect acquired changes that are present only in the cancer. Results are usually classified as pathogenic or likely pathogenic, uncertain, or benign. A variant of uncertain significance should not be used as if it were a hereditary cancer diagnosis.

  • BRCA1, BRCA2, RAD51C, RAD51D, and BRIP1 are key hereditary ovarian-cancer genes, but their risk levels and recommended timing of preventive surgery are not identical.
  • Lynch syndrome genes are especially important for endometrial cancer and also increase ovarian and colorectal cancer risk, with management tailored to the specific gene.
  • A pathogenic germline result can affect relatives because most of these syndromes are autosomal dominant, giving each first-degree relative a 50% chance of carrying the familial variant.
  • A variant of uncertain significance is not an actionable positive result and should not determine surgery or family testing on its own.
  • Germline and tumor testing answer different questions, and a tumor-only pathogenic finding may need confirmation in blood or saliva before it is called inherited.

Table of Contents

What a Gynecologic Cancer Gene Panel Tests

A hereditary cancer panel analyzes multiple genes at the same time because ovarian and endometrial cancer predisposition can arise from several syndromes with overlapping family histories. Testing one gene at a time may miss an unexpected cause, especially when more than one hereditary syndrome could explain the cancer pattern.

For ovarian, fallopian tube, and primary peritoneal cancer, panels commonly include BRCA1 and BRCA2 along with other homologous-recombination repair genes such as RAD51C, RAD51D, BRIP1, and often PALB2. For endometrial cancer, Lynch syndrome genes are central. Depending on age at diagnosis, histology, tumor findings, and family history, broader panels may include PTEN, STK11, TP53, or additional genes associated with rarer syndromes.

The test is usually performed on germline DNA from blood or saliva. A germline pathogenic variant is present throughout the body and can be inherited by children. This differs from a mutation found only in tumor tissue, which may have arisen after conception and may not be present in relatives.

Panel size should match the clinical question. The ASCO guideline on germline panel selection recommends considering a multigene panel when more than one gene is relevant based on the patient’s personal and family history. Broader is not always better: adding genes with uncertain or weak disease associations can increase the chance of ambiguous results without improving care.

Before testing, the clinician or genetic counselor should document cancers in first- and second-degree relatives, ages at diagnosis when known, ancestry, multiple primary cancers, and prior genetic results in the family. The best test for an unaffected relative is often targeted testing for a known familial pathogenic variant rather than repeating a broad panel from scratch.

A panel is a risk test, not a test for whether cancer is currently present. Someone without cancer can carry a pathogenic variant, while someone with ovarian or endometrial cancer can have a negative germline panel because the cancer was sporadic or caused by a gene not detected by the assay.

BRCA1, BRCA2, RAD51, and BRIP1

BRCA1 and BRCA2 are tumor-suppressor genes involved in homologous recombination, a high-fidelity pathway for repairing double-strand DNA breaks. Pathogenic germline variants substantially increase the risk of tubo-ovarian cancer and breast cancer. The magnitude and age pattern of ovarian risk differ between BRCA1 and BRCA2, which is why preventive-surgery timing is gene-specific.

A dedicated BRCA1 and BRCA2 test may be ordered alone in a family with a known BRCA variant, but a multigene panel is often more efficient when no familial cause has been established. BRCA results can also influence ovarian-cancer treatment because homologous-recombination deficiency can increase sensitivity to platinum chemotherapy and PARP-inhibitor strategies in appropriate disease settings.

RAD51C and RAD51D also function in homologous recombination. Pathogenic variants are associated with a moderate increase in tubo-ovarian cancer risk. The risk is lower on average than the risk associated with BRCA1 but still high enough to support gene-specific preventive discussions. A RAD51C and RAD51D result should be interpreted with age and family history because individual risk can vary.

BRIP1 interacts with BRCA1 and participates in DNA repair. Pathogenic germline variants are established ovarian-cancer predisposition findings. They do not simply mean “a milder BRCA1.” Cancer spectrum, penetrance, and management evidence are different. A BRIP1 pathogenic variant mainly changes ovarian-risk counseling and should not be assumed to carry the same breast-cancer risk as BRCA1 or BRCA2.

Recent ACMG guidance treats RAD51C, RAD51D, and BRIP1 as moderate-penetrance ovarian-cancer genes and emphasizes personalized risk estimates. Family history can shift the estimated absolute risk, particularly for RAD51C and RAD51D. Preventive surgery is generally discussed near the age when gene-specific ovarian risk becomes clinically important rather than using one age for all three genes.

Other homologous-recombination genes may appear on a panel, but the evidence for ovarian risk is not equal across all of them. A laboratory’s inclusion of a gene does not automatically mean that a pathogenic variant has a proven gynecologic-cancer management pathway.

Lynch Syndrome Genes and Gynecologic Risk

Lynch syndrome is caused by pathogenic germline variants that disrupt DNA mismatch repair. The main genes are MLH1, MSH2, MSH6, and PMS2; deletions involving EPCAM can silence neighboring MSH2 and also cause Lynch syndrome.

Endometrial cancer is one of the most common sentinel cancers in Lynch syndrome and may occur before colorectal cancer. Ovarian cancer risk is also increased, although the magnitude varies substantially by gene. This is why endometrial tumor testing for mismatch-repair deficiency has become an important route to identifying patients who may benefit from germline evaluation.

Tumor MMR immunohistochemistry examines MLH1, PMS2, MSH2, and MSH6 protein expression. Loss of MSH2/MSH6, isolated MSH6, or isolated PMS2 can raise suspicion for a germline defect. MLH1/PMS2 loss is common but often results from acquired MLH1 promoter methylation in the tumor, so methylation testing helps decide whether a hereditary workup is needed.

A normal tumor MMR screen lowers suspicion but does not erase a striking family history. Germline panel testing may still be appropriate if the pedigree suggests Lynch syndrome or another hereditary syndrome. Conversely, an abnormal tumor screen does not by itself diagnose Lynch syndrome; the final hereditary diagnosis requires the appropriate germline evaluation.

Risk management differs by gene. MLH1 and MSH2 generally confer higher colorectal and gynecologic risks than PMS2, while MSH6 is particularly associated with endometrial cancer. Preventive hysterectomy and removal of the fallopian tubes and ovaries can be considered after childbearing for selected carriers, but the timing and whether ovarian removal is recommended should be individualized by gene, age, menopausal effects, family history, and current guidance.

Lynch syndrome has implications far beyond the gynecologic tract. Colonoscopy is a major part of prevention, and some genes also increase risks of gastric, urinary tract, small bowel, pancreatic, or other cancers. A positive result should therefore lead to syndrome-level counseling, not just an ovarian or endometrial plan.

Who Should Consider Germline Testing

Germline testing is strongly relevant for people with epithelial ovarian, fallopian tube, or primary peritoneal cancer because hereditary pathogenic variants are common enough to affect both treatment and family risk. Current gynecologic oncology guidance supports germline testing broadly in this population rather than restricting it to patients with a strong family history.

Endometrial cancer testing is often guided by tumor MMR/MSI screening, age, histology, and family history, although broader germline testing may be appropriate in selected patients. A patient with MMR-deficient tumor findings that are not explained by MLH1 methylation should be evaluated for Lynch syndrome. Early-onset cancer, multiple Lynch-associated tumors, or a strong family history can also support germline testing.

Testing should also be considered when the family contains combinations such as ovarian cancer plus breast, pancreatic, prostate, colorectal, or endometrial cancer; multiple relatives with the same cancer; cancers occurring unusually young; bilateral or multiple primary tumors; or a known pathogenic variant in a blood relative.

Ancestry can change the prior probability of particular founder variants, but ancestry alone should not be used to deny testing to someone who otherwise meets criteria. Likewise, a small family can hide hereditary risk because there may be few female relatives, early deaths, adoption, limited information, or relatives who have not yet reached the ages at which cancer usually appears.

Genetic testing is most informative when it begins with an affected relative if one is available. Finding a pathogenic variant in that person creates a clear target for relatives. Testing an unaffected relative first can still be appropriate, but a negative result may be less conclusive when the family’s underlying cause has never been identified.

Pretest counseling should cover possible results, insurance and privacy considerations relevant to the patient’s country, effects on relatives, reproductive implications, and the possibility of discovering risk for cancers outside gynecology. The goal is informed testing, not simply ordering the largest available panel.

Positive, Negative, and Uncertain Results

A pathogenic or likely pathogenic germline variant is generally considered an actionable positive result when the gene has an established disease association. The next question is not just “Is it positive?” but “What cancer risks are proven for this gene, at what ages, and what interventions reduce those risks?”

For most hereditary gynecologic cancer syndromes, inheritance is autosomal dominant. A person with one pathogenic variant has a 50% chance of passing it to each child, and each full sibling often has a 50% chance of carrying it as well if one parent is a carrier. This makes cascade testing of adult relatives one of the most important benefits of identifying the familial variant.

A negative result has several meanings. If a patient tests negative for a known familial variant, that is a true negative for that specific inherited risk. If no familial variant has ever been identified, however, a negative broad panel is an “uninformative negative.” It lowers the chance of the tested syndromes but cannot prove that the family’s cancer clustering is nonhereditary.

A variant of uncertain significance (VUS) means the laboratory does not have enough evidence to classify the change as pathogenic or benign. A VUS should not trigger risk-reducing surgery, intensified screening, or predictive testing of healthy relatives as though it were a pathogenic variant. Management should be based on the patient’s personal and family history until the variant is reclassified.

VUS rates increase as panels become larger and as testing includes genes with less evidence or populations underrepresented in genetic databases. Reclassification happens over time. Patients should keep contact information current with the ordering clinic or laboratory when possible, but they should not assume every VUS will eventually become pathogenic; many are downgraded to benign or likely benign.

Sometimes a panel identifies a pathogenic variant in a gene that does not clearly explain the cancer being treated. That result can still matter for future risk, but clinicians should avoid forcing causality. The gene’s established cancer spectrum should determine management.

How Results Change Risk Management

The most important principle is that risk-reducing surgery is gene-specific. BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, and Lynch syndrome genes do not all carry the same ovarian-risk curve, so they should not all produce the same recommendation at the same age.

For BRCA1 and BRCA2 carriers, risk-reducing salpingo-oophorectomy after childbearing is a well-established strategy that substantially reduces tubo-ovarian cancer risk. The recommended timing is generally earlier for BRCA1 than BRCA2 because BRCA1-associated ovarian cancer tends to occur at younger ages. Menopausal consequences, fertility, breast-cancer history, and hormone-therapy considerations are part of the decision.

For BRIP1, RAD51C, and RAD51D carriers, recent guidance supports discussing risk-reducing salpingo-oophorectomy closer to the age of menopause based on gene-specific age-related risk and family history. Removing ovaries too early can cause cardiovascular, bone, sexual, cognitive, and quality-of-life harms from premature menopause, so surgery should not be scheduled solely because a panel says “positive.”

For Lynch syndrome, risk-reducing hysterectomy can prevent endometrial cancer after childbearing. Whether and when to remove the ovaries is more gene-dependent because ovarian risk is not equal for MLH1, MSH2, MSH6, and PMS2. Colonoscopy and other syndrome-specific surveillance remain essential even after gynecologic risk-reducing surgery.

Screening is not equally effective for every cancer. There is no ovarian screening strategy proven to match the mortality reduction achieved by appropriately timed risk-reducing surgery in high-risk hereditary syndromes. CA-125 and transvaginal ultrasound may be used selectively in some circumstances, but a normal result cannot guarantee that early ovarian cancer is absent.

A hereditary result can also affect treatment after cancer develops. BRCA-related homologous-recombination defects can support PARP-inhibitor strategies in ovarian cancer according to disease setting and current approvals. Mismatch-repair deficiency or MSI-high status can support immunotherapy in appropriate endometrial or other cancers. Treatment eligibility, however, often depends on tumor biomarkers in addition to the inherited result.

Germline Versus Tumor Testing

Germline and somatic testing overlap, but they are not substitutes. Germline testing examines inherited DNA, usually from blood or saliva. Tumor testing examines DNA or proteins within the cancer and can detect both inherited variants that are present in the tumor and acquired alterations that arose only in the malignant cells.

Ovarian cancer is a good example. Germline BRCA testing identifies inherited BRCA1/2 variants, while tumor sequencing can also find somatic BRCA mutations. Tumor assays may assess a broader homologous recombination deficiency profile that reflects genomic scarring rather than a single inherited gene. These findings can affect treatment but do not automatically define hereditary risk.

If tumor-only sequencing detects a pathogenic variant in BRCA1, BRCA2, an MMR gene, or another hereditary-cancer gene, the patient may need confirmatory germline testing. Tumor variant allele fraction alone usually cannot prove whether a variant was inherited. Conversely, a negative tumor panel does not necessarily replace a properly designed germline assay because coverage and laboratory methods differ.

In endometrial cancer, tumor MMR IHC and MSI testing are particularly useful as functional screens for mismatch-repair deficiency. When the pattern suggests Lynch syndrome, germline testing answers the hereditary question. In ovarian cancer, both germline and somatic testing may be recommended because each can reveal clinically useful findings missed by the other.

When reviewing a genetic report, verify the sample type, gene, exact variant, classification, and whether the finding is germline or tumor-only. Ask what the result changes today: treatment, preventive surgery, screening, testing of relatives, or nothing yet. A result that changes none of those may still be worth documenting, but it should not be overinterpreted.

The strongest use of a gynecologic cancer gene panel is therefore coordinated care. Oncology uses results for treatment and future cancer risk; genetics clarifies inheritance and family testing; gynecology and other specialists implement prevention; and relatives can pursue targeted testing when a familial pathogenic variant is known. That coordinated interpretation turns a technical sequencing report into a practical hereditary-cancer plan.

References

Disclaimer

This article provides general information and does not replace personalized genetic counseling, oncology care, or medical advice. Cancer risk and management depend on the exact gene and variant, age, family history, prior cancers, reproductive goals, and current guidelines. Do not use a variant of uncertain significance as the sole reason for preventive surgery or predictive testing of relatives.

RELATED ARTICLESMORE FROM AUTHOR